Michelle Spektor's Archive

Michelle is a junior at Cornell University, and is pursuing her interests in scientific research, medical ethics, and science communication by majoring in Biology and Society with a minor in Science and Technology Studies. She joined the Myeloma Beacon team in June 2010. Besides avidly writing for the Beacon, Michelle also enjoys drinking unusual teas, reading poetry, thrift shopping, and participating in and supporting the creative and performing arts at Cornell.

Michelle Spektor has written 22 article(s) .

Carfilzomib May Benefit Relapsed And Refractory Multiple Myeloma Patients (ASCO 2010)
[ by | Jun 14, 2010 11:08 am | 3 Comments ]
Carfilzomib May Benefit Relapsed And Refractory Multiple Myeloma Patients (ASCO 2010)

An ongoing Phase 2 trial of carfilzomib has demonstrated that carfilzomib may be effective in treating relapsed/refractory multiple myeloma patients, including patients who are resistant to or relapsed after Velcade (bortezomib) treatment. The results were presented by Dr. Ravi Vij of Washington University in St. Louis at the annual American Society of Clinical Oncology (ASCO) meeting in Chicago on June 5.

“Single agent carfilzomib has demonstrated significant activity in relapsed/refractory myeloma,” said Dr. Vij during his presentation.

Carfilzomib,…

Tags: , , , ,
Read the full story »
Reduced-Dose Velcade-Thalidomide-Dexamethasone Combination Shows Promise As Initial Therapy Prior To Stem Cell Transplantation (ASCO 2010)
[ by | Jun 11, 2010 4:48 pm | 6 Comments ]
Reduced-Dose Velcade-Thalidomide-Dexamethasone Combination Shows Promise As Initial Therapy Prior To Stem Cell Transplantation (ASCO 2010)

The combination treatment of reduced-dose Velcade (bortezomib), thalidomide (Thalomid), and dexamethasone (Decadron), abbreviated vTD, appears to be a safe and effective induction treatment for newly diagnosed multiple myeloma patients prior to stem cell transplantation.

The combination treatment yielded higher complete and partial remission rates, and fewer and less severe side effects, than treatment with standard dose Velcade plus dexamethasone (VD).

The vTD vs. VD findings were presented by Dr. Philippe Moreau of the University Hospital in Nantes,…

Tags: , , , , ,
Read the full story »
Page 5 of 512345